A novel oncogenic function of Wilms tumor gene WT1 in leukemia

肾母细胞瘤基因 WT1 在白血病中的新致癌功能

• 批准号: 15K09476
• 负责人: Oji Yusuke
• 金额: $ 3.08万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2015
• 资助国家: 日本
• 起止时间: 2015-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K09476/
• 关键词: WT1; leukemia; 白血病; 分子標的治療法

项目成果

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

树突状细胞疫苗接种作为缓解后治疗以预防或延缓急性髓系白血病复发

• DOI: 10.1182/blood-2017-04-780155
• 发表时间: 2017
• 影响因子: 20.3
• 作者: Anguille Sebastien;et al
• 通讯作者: et al

Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.

肾母细胞瘤 1 肽疫苗作为一种以治愈为导向的化疗后策略，用于治疗高复发风险的急性髓系白血病患者。

• DOI: 10.1111/bjh.14768
• 发表时间: 2017
• 作者: Nakata J; Nakae Y; Kawakami M; Morimoto S; Motooka D; Hosen N; Fujiki F; Nakajima H; Hasegawa K; Nishida S; Tsuboi A; Oji Y; Oka Y; Kumanogoh A; Sugiyama H.
• 通讯作者: Sugiyama H.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.

鉴定出对主要 WT1 同工型具有拮抗作用的新型 C 端截短 WT1 同工型。

• DOI: 10.1371/journal.pone.0130578
• 发表时间: 2015
• 影响因子: 3.7
• 作者: Tatsumi N; Hojo N; Sakamoto H; Inaba R; Moriguchi N; Matsuno K; Fukuda M; Matsumura A; Hayashi S; Morimoto S; Nakata J; Fujiki F; Nishida S; Nakajima H; Tsuboi A; Oka Y; Hosen N; Sugiyama H; Oji Y.
• 通讯作者: Oji Y.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.

针对 WT1 肽的 WT1 IgG 抗体与接种 WT1 肽疫苗的多形性胶质母细胞瘤患者延长生存期的关联。

• DOI: 10.1002/ijc.30182
• 发表时间: 2016
• 作者: Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y
• 通讯作者: Oka Y

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

Syndecan-4 作为生物标志物来预测 WT1 肽疫苗治疗的多形性胶质母细胞瘤的临床结果。

• 发表时间: 2016
• 作者: Takashima S; Oka Y; Fujiki F; Morimoto S; Nakajima H; Nakae Y; Nakata J; Nishida S; Hosen N; Tatsumi N; Mizuguchi K; Hashimoto N; Oji Y; Tsuboi A; Kumanogoh A; Sugiyama H.
• 通讯作者: Sugiyama H.